Lipocine Inc. (LPCN) Stock Price

LPCNStock

$2.15−33.76%52W

Market Cap$17.73M

P/E6416.73x

PEG Ratio—

Div yield—

Beta0.36

LPCN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-89.17%

Price vs S&P 500 (4W)-6.79%

VGM Score55.85

P/E Ratio (Annual)6416.73x

Book Value / Share (Quarterly)$3.05

P/TBV (Annual)0.37x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)58.12%

Cash Flow / Share (Quarterly)$-1.34

Price vs S&P 500 (YTD)-86.31%

Net Profit Margin (TTM)-571.09%

EPS (TTM)$-1.96

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-1.96

Revenue Growth (5Y)133.89%

EPS (Annual)$-1.77

ROI (Annual)-66.50%

Net Profit Margin (5Y Avg)-2154.83%

Cash / Share (Quarterly)$3.31

Revenue Growth QoQ (YoY)27.21%

P/E Normalized (Annual)6416.73x

ROA (Last FY)-56.61%

Revenue Growth TTM (YoY)-45.52%

EBITD / Share (TTM)$-2.08

ROE (5Y Avg)-35.66%

Operating Margin (TTM)-605.86%

Cash Flow / Share (Annual)$-1.58

P/B Ratio0.74x

P/B Ratio (Quarterly)2.62x

Net Income / Employee (Annual)$-687,700

EV / Revenue (TTM)5.98x

Net Interest Coverage (TTM)-3.50x

ROA (TTM)-59.39%

EV / EBITDA (TTM)3.44x

EPS Incl Extra (Annual)$-1.77

Current Ratio (Annual)6.68x

Quick Ratio (Quarterly)9.87x

3-Month Avg Trading Volume0.10M

52-Week Price Return-33.76%

Revenue / Employee (TTM)$143,000

Tangible BV / Share (Quarterly)$4.23

P/S Ratio (Annual)8.59x

Asset Turnover (Annual)0.12x

52-Week High$12.37

Operating Margin (5Y Avg)-2195.35%

EPS Excl Extra (Annual)$-1.77

Tangible BV CAGR (5Y)13.43%

26-Week Price Return-77.92%

Quick Ratio (Annual)6.36x

13-Week Price Return-7.21%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)9.99x

Enterprise Value$11.97M

Revenue / Share Growth (5Y)81.34%

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-8.79%

Revenue / Employee (Annual)$141,200

Pretax Margin (Annual)-487.04%

Cash / Share (Annual)$2.42

3-Month Return Std Dev46.38%

Net Income / Employee (TTM)$-816,800

ROE (Last FY)-66.50%

Net Interest Coverage (Annual)-3.57x

EPS Basic Excl Extra (Annual)$-1.77

P/FCF (TTM)4.15x

Receivables Turnover (TTM)13.79x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.96

Receivables Turnover (Annual)29.36x

ROI (TTM)-66.69%

P/S Ratio (TTM)8.48x

Pretax Margin (5Y Avg)-2154.82%

Revenue / Share (Annual)$0.36

Tangible BV / Share (Annual)$6.84

Price vs S&P 500 (52W)-52.07%

Year-to-Date Return-74.35%

5-Day Price Return0.98%

EPS Normalized (Annual)$-1.77

ROA (5Y Avg)-31.50%

Net Profit Margin (Annual)-487.05%

Month-to-Date Return-2.83%

Cash Flow / Share (TTM)$-3.09

EBITD / Share (Annual)$-1.89

Operating Margin (Annual)-524.69%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-35.65%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.96

P/TBV (Quarterly)0.59x

P/B Ratio (Annual)3.08x

Pretax Margin (TTM)-571.09%

Book Value / Share (Annual)$2.35

Price vs S&P 500 (13W)-10.00%

Beta0.36x

Revenue / Share (TTM)$0.29

ROE (TTM)-66.69%

52-Week Low$1.81

vGradeB

gGradeB

mGradeD

vgmGradeC

LPCN Earnings Surprise History

Q2 25-0.41est. -0.40

Q3 25-0.59est. -0.54

Q4 25-0.42est. -0.61

Q1 26-0.54est. -0.48

Q2 26-0.32est. -0.40

LPCN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
LPCNLipocine Inc.	B	B	D	$2.15
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Lipocine Inc.

Lipocine is a clinical-stage biopharmaceutical company developing oral drug delivery solutions using proprietary technology. Its lead product, TLANDO, is an oral testosterone replacement therapy. The company is advancing a pipeline of additional candidates including TLANDO XR and compounds designated LPCN 1144, LPCN 1148, LPCN 1107, and LPCN 1154, developed both internally and in collaboration with corporate partners.